At Xalud Therapeutics, we aspire to transform the way chronic inflammatory disease is treated. Patients have waited far too long for a treatment option that addresses the underlying cause of their disease. To meet this need, we are clinically investigating our non-viral gene therapy, XT-150, in a number of conditions caused by chronic inflammation.
Clinical trials are an opportunity for patients to play an integral role in the study of new, potentially effective medicines. We are currently recruiting for clinical trials that are investigating XT-150: our non-viral gene therapy containing non-integrating therapeutic plasmid DNA, enabling local delivery directly to the site of inflammation. We have designed XT-150 to have an optimized regimen, dosing and formulation – significantly increasing the duration of its effects and staying within the site of injection.
Title: Safety and Efficacy of XT-150 for the Treatment of Neuropathic Pain
For more information on this study, please visit ClinicalTrials.gov.